David Y. A. Dadey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David Y. A. Dadey has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Dinesh Thotala
Washington University in St. Louis School of Medicine, St. Louis, MO
8 shared publicationsDennis Hallahan
Department of Radiation Oncology, Washington University School of Medicine , St. Louis, MO , USA
7 shared publicationsArpine Khudanyan
Department of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri
4 shared publicationsKim Nguyen
Washington University School of Medicine in St. Louis, UNITED STATES
4 shared publicationsBuck Rogers
Washington University in St. Louis School of Medicine, St. Louis, MO
3 shared publicationsDaniel J. Ferraro
Washington University in St. Louis School of Medicine, St. Louis, MO
3 shared publications
Latest Publications
- 5 September 2022
- Published by Elsevier in World Neurosurgery
- Vol. 167, e953-e961
Assessment of the Neurosurgical Capacity in Ghana: Challenges and Opportunities
- 5 September 2022
- Published by Elsevier in World Neurosurgery
- Vol. 167, e953-e961
Assessment of the Neurosurgical Capacity in Ghana: Challenges and Opportunities
- 14 May 2017
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (10) , 2556-2564
Antibody Targeting GRP78 Enhances the Efficacy of Radiation Therapy in Human Glioblastoma and Non–Small Cell Lung Cancer Cell Lines and Tumor Models
Purpose: Non–small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM) have poor median survival. NSCLC and GBM overexpress glucose regulated protein 78 (GRP78), which has a role in radioresistance and recurrence. In this study, we determined the effect of anti-GRP78 antibody and the combined effect of the anti-GRP78 antibody with ionizing radiation (XRT) on NSCLC and GBM cell lines both in vitro and in vivo. Experimental Design: NSCLC and GBM cancer cell lines were treated with anti-GRP78 antibodies and evaluated for proliferation, colony formation, cell death, and PI3K/Akt/mTOR signaling. The efficacy of anti-GRP78 antibodies on tumor growth in combination with XRT was determined in vivo in mouse xenograft models. Results: GBM and NSCLC cells treated with anti-GRP78 antibodies showed attenuated cell proliferation, colony formation, and enhanced apoptosis. GBM and NSCLC cells treated with anti-GRP78 antibodies also showed global suppression of PI3K/Akt/mTOR signaling. Combining antibody with XRT resulted in significant tumor growth delay in both NSCLC and GBM heterotopic tumor models. Conclusions: Antibodies targeting GRP78 exhibited antitumor activity and enhanced the efficacy of radiation in NSCLC and GBM both in vitro and in vivo. GRP78 is a promising novel target, and anti-GRP78 antibodies could be used as an effective cancer therapy alone or in combination with XRT. Clin Cancer Res; 23(10); 2556–64. ©2016 AACR.
- 14 May 2017
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (10) , 2556-2564
Antibody Targeting GRP78 Enhances the Efficacy of Radiation Therapy in Human Glioblastoma and Non–Small Cell Lung Cancer Cell Lines and Tumor Models
Purpose: Non–small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM) have poor median survival. NSCLC and GBM overexpress glucose regulated protein 78 (GRP78), which has a role in radioresistance and recurrence. In this study, we determined the effect of anti-GRP78 antibody and the combined effect of the anti-GRP78 antibody with ionizing radiation (XRT) on NSCLC and GBM cell lines both in vitro and in vivo. Experimental Design: NSCLC and GBM cancer cell lines were treated with anti-GRP78 antibodies and evaluated for proliferation, colony formation, cell death, and PI3K/Akt/mTOR signaling. The efficacy of anti-GRP78 antibodies on tumor growth in combination with XRT was determined in vivo in mouse xenograft models. Results: GBM and NSCLC cells treated with anti-GRP78 antibodies showed attenuated cell proliferation, colony formation, and enhanced apoptosis. GBM and NSCLC cells treated with anti-GRP78 antibodies also showed global suppression of PI3K/Akt/mTOR signaling. Combining antibody with XRT resulted in significant tumor growth delay in both NSCLC and GBM heterotopic tumor models. Conclusions: Antibodies targeting GRP78 exhibited antitumor activity and enhanced the efficacy of radiation in NSCLC and GBM both in vitro and in vivo. GRP78 is a promising novel target, and anti-GRP78 antibodies could be used as an effective cancer therapy alone or in combination with XRT. Clin Cancer Res; 23(10); 2556–64. ©2016 AACR.
- 1 November 2016
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 18 (suppl_6) , vi45
CSIG-20. IDENTIFICATION OF A NAMPT-E2F2-ID1 SIGNALING AXIS IN GLIOBLASTOMA
Emerging evidence shows that nicotinamide adenine dinucleotide (NAD+)-dependent signaling plays a critical role in a variety of biological contexts including cancer. The rate-limiting enzyme of the mammalian NAD+ synthesis pathway, nicotinamide phosphoribosyltransferase (NAMPT), governs NAD+-dependent processes by catalyzing production of nicotinamide mononucleotide (NMN), a key NAD+ precursor. However, the role and molecular mechanisms of NAMPT in the biology of human glioblastoma have remained poorly understood. Here, we demonstrate that NAMPT is highly expressed in glioblastoma tumor specimens and patient-derived glioblastoma stem-like cells (GSCs). High NAMPT expression in glioblastoma tumors correlates with poor prognosis in patients. NAMPT inhibition using FK866 as well as RNA interference (RNAi) depleted NAD+ levels in GSCs and substantially decreased GSC self-renewal. Importantly, NAMPT knockdown diminished the in vivo tumorigenicity of GSCs and prolonged the survival of animals in an orthotopic xenograft model. Bioinformatic analysis of RNA-sequencing data derived from FK866-treated GSCs revealed E2F family transcription factor E2F2 as a potential hub of the NAD+-dependent transcriptome. Accordingly, E2F2 knockdown decreased the self-renewal capacity of GSCs. Downstream, we find that E2F2 directly controls the transcription of helix-loop-helix protein inhibitor of differentiation 1 (ID1), a known regulator of self-renewal. Finally, we show that NAMPT promotes radiation resistance of GSCs in culture, highlighting the potential therapeutic relevance of this pathway. The identification of a NAMPT-E2F2-ID1 signaling pathway, which regulates GSC maintenance, has ramifications for the development of novel therapeutic strategies for glioblastoma patients.
- 1 November 2016
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 18 (suppl_6) , vi45
CSIG-20. IDENTIFICATION OF A NAMPT-E2F2-ID1 SIGNALING AXIS IN GLIOBLASTOMA
Emerging evidence shows that nicotinamide adenine dinucleotide (NAD+)-dependent signaling plays a critical role in a variety of biological contexts including cancer. The rate-limiting enzyme of the mammalian NAD+ synthesis pathway, nicotinamide phosphoribosyltransferase (NAMPT), governs NAD+-dependent processes by catalyzing production of nicotinamide mononucleotide (NMN), a key NAD+ precursor. However, the role and molecular mechanisms of NAMPT in the biology of human glioblastoma have remained poorly understood. Here, we demonstrate that NAMPT is highly expressed in glioblastoma tumor specimens and patient-derived glioblastoma stem-like cells (GSCs). High NAMPT expression in glioblastoma tumors correlates with poor prognosis in patients. NAMPT inhibition using FK866 as well as RNA interference (RNAi) depleted NAD+ levels in GSCs and substantially decreased GSC self-renewal. Importantly, NAMPT knockdown diminished the in vivo tumorigenicity of GSCs and prolonged the survival of animals in an orthotopic xenograft model. Bioinformatic analysis of RNA-sequencing data derived from FK866-treated GSCs revealed E2F family transcription factor E2F2 as a potential hub of the NAD+-dependent transcriptome. Accordingly, E2F2 knockdown decreased the self-renewal capacity of GSCs. Downstream, we find that E2F2 directly controls the transcription of helix-loop-helix protein inhibitor of differentiation 1 (ID1), a known regulator of self-renewal. Finally, we show that NAMPT promotes radiation resistance of GSCs in culture, highlighting the potential therapeutic relevance of this pathway. The identification of a NAMPT-E2F2-ID1 signaling pathway, which regulates GSC maintenance, has ramifications for the development of novel therapeutic strategies for glioblastoma patients.
- 1 October 2016
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Neurosurgical Focus
- Vol. 41 (4) , E4
Utilizing personalized stereotactic frames for laser interstitial thermal ablation of posterior fossa and mesiotemporal brain lesions: a single-institution series
OBJECTIVE: The precision of laser probe insertion for interstitial thermal therapy of deep-seated lesions is limited by the method of stereotactic guidance. The objective of this study was to evaluate the feasibility of customized STarFix 3D-printed stereotactic platforms to guide laser probe insertion into mesiotemporal and posterior fossa targets. METHODS: The authors conducted a retrospective review of 5 patients (12–55 years of age) treated with laser interstitial thermal therapy (LITT) in which STarFix platforms were used for probe insertion. Bone fiducials were implanted in each patient's skull, and subsequent CT scans were used to guide the design of each platform and incorporate desired treatment trajectories. Once generated, the platforms were mounted on the patients' craniums and used to position the laser probe during surgery. Placement of the laser probe and the LITT procedure were monitored with intraoperative MRI. Perioperative and follow-up MRI were performed to identify and monitor changes in target lesions. RESULTS: Accurate placement of the laser probe was observed in all cases. For all patients, thermal ablation was accomplished without intraoperative complications. Of the 4 patients with symptomatic lesions, 2 experienced complete resolution of symptoms, and 1 reported improved symptoms compared with baseline. CONCLUSIONS: Customized stereotactic platforms were seamlessly incorporated into the authors' previously established LITT workflow and allowed for accurate treatment delivery.
- 1 October 2016
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Neurosurgical Focus
- Vol. 41 (4) , E4
Utilizing personalized stereotactic frames for laser interstitial thermal ablation of posterior fossa and mesiotemporal brain lesions: a single-institution series
OBJECTIVE: The precision of laser probe insertion for interstitial thermal therapy of deep-seated lesions is limited by the method of stereotactic guidance. The objective of this study was to evaluate the feasibility of customized STarFix 3D-printed stereotactic platforms to guide laser probe insertion into mesiotemporal and posterior fossa targets. METHODS: The authors conducted a retrospective review of 5 patients (12–55 years of age) treated with laser interstitial thermal therapy (LITT) in which STarFix platforms were used for probe insertion. Bone fiducials were implanted in each patient's skull, and subsequent CT scans were used to guide the design of each platform and incorporate desired treatment trajectories. Once generated, the platforms were mounted on the patients' craniums and used to position the laser probe during surgery. Placement of the laser probe and the LITT procedure were monitored with intraoperative MRI. Perioperative and follow-up MRI were performed to identify and monitor changes in target lesions. RESULTS: Accurate placement of the laser probe was observed in all cases. For all patients, thermal ablation was accomplished without intraoperative complications. Of the 4 patients with symptomatic lesions, 2 experienced complete resolution of symptoms, and 1 reported improved symptoms compared with baseline. CONCLUSIONS: Customized stereotactic platforms were seamlessly incorporated into the authors' previously established LITT workflow and allowed for accurate treatment delivery.
- 1 October 2016
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Neurosurgical Focus
- Vol. 41 (4) , E9
Laser interstitial thermal therapy for subependymal giant cell astrocytoma: technical case report
Subependymal giant cell astrocytoma (SEGA) is a rare tumor occurring almost exclusively in patients with tuberous sclerosis complex. Although open resection remains the standard therapy, complication rates remain high. To minimize morbidity, less invasive approaches, such as endoscope-assisted resection, radiosurgery, and chemotherapy with mTOR pathway inhibitors, are also used to treat these lesions. Laser interstitial thermal therapy (LITT) is a relatively new modality that is increasingly used to treat a variety of intracranial lesions. In this report, the authors describe two pediatric cases of SEGA that were treated with LITT. In both patients the lesion responded well to this treatment modality, with tumor shrinkage observed on follow-up MRI. These cases highlight the potential of LITT to serve as a viable minimally invasive therapeutic approach to the management of SEGAs in the pediatric population.
- 1 October 2016
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Neurosurgical Focus
- Vol. 41 (4) , E9
Laser interstitial thermal therapy for subependymal giant cell astrocytoma: technical case report
Subependymal giant cell astrocytoma (SEGA) is a rare tumor occurring almost exclusively in patients with tuberous sclerosis complex. Although open resection remains the standard therapy, complication rates remain high. To minimize morbidity, less invasive approaches, such as endoscope-assisted resection, radiosurgery, and chemotherapy with mTOR pathway inhibitors, are also used to treat these lesions. Laser interstitial thermal therapy (LITT) is a relatively new modality that is increasingly used to treat a variety of intracranial lesions. In this report, the authors describe two pediatric cases of SEGA that were treated with LITT. In both patients the lesion responded well to this treatment modality, with tumor shrinkage observed on follow-up MRI. These cases highlight the potential of LITT to serve as a viable minimally invasive therapeutic approach to the management of SEGAs in the pediatric population.
- Open Access
- 21 July 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (12) , 1991-1997
Tumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers
Cancer specific targeting sparing normal tissues would significantly enhance cancer therapy outcomes and reduce cancer-related mortality. One approach is to target receptors and/or molecules that are specifically expressed on cancer cells. Peptides as cancer-specific targeting agents offer advantages such as ease of synthesis, low antigenicity and enhanced diffusion into tissues. Glucose regulated protein 78 (GRP78) is an endoplasmic reticulum stress chaperone that regulates the unfolded protein response and is over expressed in various cancers. In this study we evaluated GIRLRG peptide that specifically targets GRP78 for cancer specific binding (in vitro) and non-invasive tumor imaging (in vivo). Methods: GIRLRG peptide was modeled into the GRP78 ATPase domain using computational modeling. Surface Plasmon Resonance studies were performed to determine the affinity of GIRLRG peptide to GRP78 protein. GIRLRG was conjugated with PEG to prolong its circulation in mice. Tumor binding efficacy of PEG-GIRLRG peptide was evaluated in nude mice bearing heterotopic cervical (HT3), esophageal (OE33), pancreatic (BXPC3), lung (A549) and glioma (D54) tumors. NanoSPECT/CT imaging of the mice was performed 48 h and 72 h after injecting with 111Indium (111In) labeled PEG-GIRLRG or PEG-control peptide. Post-SPECT biodistribution studies were performed 96 h post-injection of the radiolabeled peptides. Results: Using molecular modeling and surface plasmon resonance, we identified that GIRLRG was binding with a KD of 2.16 X 10-3 M in the ATPase domain of GRP78. GIRLRG peptide specifically bound to cervical, lung, esophageal and glioma cells. SPECT imaging revealed that 111In-PEG-GIRLRG specifically bound to cervical, esophageal, pancreatic, lung and brain tumors. Post SPECT biodistribution data also validated the SPECT imaging results. Conclusion: GIRLRG peptide specifically binds to the ATPase domain of GRP78. Radiolabeled PEG-GIRLRG could be used to target various cancers. Further studies would be required to translate PEG-GIRLRG peptide into the clinic.
- 21 July 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (12) , 1991-1997
Open AccessTumor-Specific Binding of Radiolabeled PEGylated GIRLRG Peptide: A Novel Agent for Targeting Cancers
Cancer specific targeting sparing normal tissues would significantly enhance cancer therapy outcomes and reduce cancer-related mortality. One approach is to target receptors and/or molecules that are specifically expressed on cancer cells. Peptides as cancer-specific targeting agents offer advantages such as ease of synthesis, low antigenicity and enhanced diffusion into tissues. Glucose regulated protein 78 (GRP78) is an endoplasmic reticulum stress chaperone that regulates the unfolded protein response and is over expressed in various cancers. In this study we evaluated GIRLRG peptide that specifically targets GRP78 for cancer specific binding (in vitro) and non-invasive tumor imaging (in vivo). Methods: GIRLRG peptide was modeled into the GRP78 ATPase domain using computational modeling. Surface Plasmon Resonance studies were performed to determine the affinity of GIRLRG peptide to GRP78 protein. GIRLRG was conjugated with PEG to prolong its circulation in mice. Tumor binding efficacy of PEG-GIRLRG peptide was evaluated in nude mice bearing heterotopic cervical (HT3), esophageal (OE33), pancreatic (BXPC3), lung (A549) and glioma (D54) tumors. NanoSPECT/CT imaging of the mice was performed 48 h and 72 h after injecting with 111Indium (111In) labeled PEG-GIRLRG or PEG-control peptide. Post-SPECT biodistribution studies were performed 96 h post-injection of the radiolabeled peptides. Results: Using molecular modeling and surface plasmon resonance, we identified that GIRLRG was binding with a KD of 2.16 X 10-3 M in the ATPase domain of GRP78. GIRLRG peptide specifically bound to cervical, lung, esophageal and glioma cells. SPECT imaging revealed that 111In-PEG-GIRLRG specifically bound to cervical, esophageal, pancreatic, lung and brain tumors. Post SPECT biodistribution data also validated the SPECT imaging results. Conclusion: GIRLRG peptide specifically binds to the ATPase domain of GRP78. Radiolabeled PEG-GIRLRG could be used to target various cancers. Further studies would be required to translate PEG-GIRLRG peptide into the clinic.
- 15 July 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (14_Supplem) , 4202
Abstract 4202: Peptide probes binding to radiation-inducible cell surface GRP78 as a novel targeting strategy for various tumors
Traditional radiation therapy is often associated with significant toxicity to normal cells that could limit the success of cancer therapy. The greater understanding in the molecular differences between cancer cells and normal cells has lead to targeted therapies in cancer treatment. We have discovered novel radiation-inducible antigens in cancer using phage-display peptide libraries. One such inducible-antigen is Glucose regulated protein 78kDa (GRP78) that was shown to bind the hexapeptide GIRLRG. GRP78 is known to regulate cellular stresses, including hypoglycemia, hypoxia and the ER stress response. It is over-expressed in different cancer subtypes and has been correlated to their poor prognosis. In this study, we evaluated the cell surface induction of GRP78 post irradiation (IR) on lung cancer (A549 and LLC), glioma (D54 and GL261) and endothelial (HUVEC and 3B11) cell lines using flow cytometry. Significantly higher surface expression of GRP78 was observed in all cell lines. We determined the specificity of GIRLRG to bind tumors in vivo using nano SPECT technology. GIRLRG was conjugated to a 40KDa PEG (for longer circulation time) and radiolabelled with 111Indium (111In) using diethylene triamine pentaacetic acid (DTPA) as the chelator. The A549 tumor bearing nude mice were irradiated (3Gy x 3 times) or sham irradiated prior to tail vein injections of 111In labeled GIRLRG. The mice were imaged 48h and 96h post injection using nano CT-SPECT imager. The SPECT images revealed that GIRLRG specifically bound to the irradiated A549 tumors while little or no binding was seen in the sham irradiated tumors. The post-SPECT imaging bio-distrubution also revealed maximum uptake in irradiated tumors. We further evaluated tumor binding of GIRLRG in Glioma (D54), esophageal cancer (OE33), cervical cancer (HT3), and pancreatic cancer (BxPC3). The nano-SPECT imaging showed that GIRLRG specifically bound to all the irradiated tumors tested. Phosphor images of the tumor sections showed that GIRLRG specifically bound to the tumors and not to normal tissues. In conclusion, GIRLRG peptide has high affinity to GRP78 in vitro and in vivo. Radiolabeled GIRLRG is a novel tool for imaging tumors and may be developed further as a therapeutic agent to deliver cancer specific drugs or therapeutic radioisotopes. Citation Format: Vaishali Kapoor, David Dadey, Kim Nguyen, Hua Li, Buck Rogers, Dinesh Thotala, Dennis Hallahan. Peptide probes binding to radiation-inducible cell surface GRP78 as a novel targeting strategy for various tumors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4202.
- 15 July 2016
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 76 (14_Supplem) , 4202
Abstract 4202: Peptide probes binding to radiation-inducible cell surface GRP78 as a novel targeting strategy for various tumors
Traditional radiation therapy is often associated with significant toxicity to normal cells that could limit the success of cancer therapy. The greater understanding in the molecular differences between cancer cells and normal cells has lead to targeted therapies in cancer treatment. We have discovered novel radiation-inducible antigens in cancer using phage-display peptide libraries. One such inducible-antigen is Glucose regulated protein 78kDa (GRP78) that was shown to bind the hexapeptide GIRLRG. GRP78 is known to regulate cellular stresses, including hypoglycemia, hypoxia and the ER stress response. It is over-expressed in different cancer subtypes and has been correlated to their poor prognosis. In this study, we evaluated the cell surface induction of GRP78 post irradiation (IR) on lung cancer (A549 and LLC), glioma (D54 and GL261) and endothelial (HUVEC and 3B11) cell lines using flow cytometry. Significantly higher surface expression of GRP78 was observed in all cell lines. We determined the specificity of GIRLRG to bind tumors in vivo using nano SPECT technology. GIRLRG was conjugated to a 40KDa PEG (for longer circulation time) and radiolabelled with 111Indium (111In) using diethylene triamine pentaacetic acid (DTPA) as the chelator. The A549 tumor bearing nude mice were irradiated (3Gy x 3 times) or sham irradiated prior to tail vein injections of 111In labeled GIRLRG. The mice were imaged 48h and 96h post injection using nano CT-SPECT imager. The SPECT images revealed that GIRLRG specifically bound to the irradiated A549 tumors while little or no binding was seen in the sham irradiated tumors. The post-SPECT imaging bio-distrubution also revealed maximum uptake in irradiated tumors. We further evaluated tumor binding of GIRLRG in Glioma (D54), esophageal cancer (OE33), cervical cancer (HT3), and pancreatic cancer (BxPC3). The nano-SPECT imaging showed that GIRLRG specifically bound to all the irradiated tumors tested. Phosphor images of the tumor sections showed that GIRLRG specifically bound to the tumors and not to normal tissues. In conclusion, GIRLRG peptide has high affinity to GRP78 in vitro and in vivo. Radiolabeled GIRLRG is a novel tool for imaging tumors and may be developed further as a therapeutic agent to deliver cancer specific drugs or therapeutic radioisotopes. Citation Format: Vaishali Kapoor, David Dadey, Kim Nguyen, Hua Li, Buck Rogers, Dinesh Thotala, Dennis Hallahan. Peptide probes binding to radiation-inducible cell surface GRP78 as a novel targeting strategy for various tumors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4202.
- Open Access
- 1 April 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 119, S478-S479
PO-0985: Anti-GRP 78 antibodies bind specifically to cancers enhance efficacy of radiotherapy in cancer
- 1 April 2016
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 119, S478-S479
Open AccessPO-0985: Anti-GRP 78 antibodies bind specifically to cancers enhance efficacy of radiotherapy in cancer
- 1 August 2015
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (15_Supplem) , 1791
Abstract 1791: Targeting radiation-inducible cell surface GRP78 using GIRLRG peptide as a novel imaging and therapeutic strategy for tumors
Traditional radiation therapy is often associated with significant toxicity to normal cells that could limit the success of cancer therapy. The greater understanding in the molecular differences between cancer cells and normal cells has lead to targeted therapies in cancer treatment. We have discovered novel radiation-inducible antigens in cancer using phage-display peptide libraries. One such inducible-antigen is Glucose regulated protein 78kDa (GRP78) that was shown to bind the hexapeptide GIRLRG. GRP78 is known to regulate cellular stresses, including hypoglycemia, hypoxia and the ER stress response. It is over-expressed in different cancer subtypes and has been correlated to their poor prognosis.
- 1 August 2015
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (15_Supplem) , 1791
Abstract 1791: Targeting radiation-inducible cell surface GRP78 using GIRLRG peptide as a novel imaging and therapeutic strategy for tumors
Traditional radiation therapy is often associated with significant toxicity to normal cells that could limit the success of cancer therapy. The greater understanding in the molecular differences between cancer cells and normal cells has lead to targeted therapies in cancer treatment. We have discovered novel radiation-inducible antigens in cancer using phage-display peptide libraries. One such inducible-antigen is Glucose regulated protein 78kDa (GRP78) that was shown to bind the hexapeptide GIRLRG. GRP78 is known to regulate cellular stresses, including hypoglycemia, hypoxia and the ER stress response. It is over-expressed in different cancer subtypes and has been correlated to their poor prognosis.
- 1 August 2015
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (15_Supplem) , 3323
Abstract 3323: Radiation-induced ER stress contributes to survival in glioblastoma cell lines
Glioblastoma is the most common primary malignant brain tumor in adults in the United States. While the standard of care for afflicted patients has evolved to include surgery, ionizing radiation (IR) and temozolomide chemotherapy, the prognoses of these patients remain dismal. With the median survival of glioblastoma patients remaining in the range of 12-15 months, there is an unmet need for approaches that can overcome the inherent therapeutic resistance of these tumors. In recent years, several studies have demonstrated that IR can activate pro-survival signaling that may facilitate adaptation to therapy and the development of radio-resistance. The endoplasmic reticulum stress response (ERSR) is a conserved program known to be deregulated in cancer and can mediate pro-survival signaling in the context of therapy. The ATF6, IRE1 and PERK pathways of the ERSR are known to be important mediators in the initiation of this signaling. In this research, we show for the first time that IR, a key component in glioblastoma therapy, can induce genes downstream of ATF6, IRE1 and PERK in glioblastoma cell lines. Furthermore, we identify the ATF6 and PERK-eIF2a-ATF4 pathways as important contributors to the radiation-response in glioblastoma. Our study began with the observation of protein and mRNA induction of targets associated with the ERSR in irradiated glioblastoma cell lines. In addition to ATF6 target genes, we observed robust induction of PERK target genes 48h after 6 Gy IR. This induction of PERK target genes was accompanied with increased phosphorylation of eIF2a in a time and dose-dependent manner. To evaluate the requirement of PERK for radiation-induced eIF2a phosphorylation, we used a specific inhibitor of PERK - GSK2606414, and found that PERK inhibition was sufficient to prevent radiation-induced eIF2a phosphorylation. We also analyzed expression of several genes downstream of PERK after treatment with GSK2606414, and found that PERK inhibition lead to 70-80% reduction in radiation-induction of downstream genes. Since ATF4 is downstream of PERK-eIF2a, we examined ATF4 expression in irradiated glioblastoma and found that it was also induced by radiation. Using RNA-interference, we found that knockdown of ATF4 reduced proliferation and clonogenic survival by 50%, and resulted in 38% increase in PARP cleavage in irradiated glioblastoma. We observed similar trends when we knocked down ATF6, suggesting that multiple aspects of the ERSR can contribute to the radiation response in glioblastoma. These results indicate that IR-induced activation of ER-stress signaling through PERK and ATF6 contributes to adaptive survival mechanisms in glioblastoma. Further characterization of the mechanism by which ATF6 and ATF4 mediate cell survival after irradiation may reveal novel targets for the enhancement of radiotherapy for glioblastoma. Citation Format: David Dadey, Vaishali Kapoor, Arpine Khudanyan, Dinesh Thotala, Dennis Hallahan. Radiation-induced ER stress contributes to survival in glioblastoma cell lines. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3323. doi:10.1158/1538-7445.AM2015-3323
- 1 August 2015
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (15_Supplem) , 3323
Abstract 3323: Radiation-induced ER stress contributes to survival in glioblastoma cell lines
Glioblastoma is the most common primary malignant brain tumor in adults in the United States. While the standard of care for afflicted patients has evolved to include surgery, ionizing radiation (IR) and temozolomide chemotherapy, the prognoses of these patients remain dismal. With the median survival of glioblastoma patients remaining in the range of 12-15 months, there is an unmet need for approaches that can overcome the inherent therapeutic resistance of these tumors. In recent years, several studies have demonstrated that IR can activate pro-survival signaling that may facilitate adaptation to therapy and the development of radio-resistance. The endoplasmic reticulum stress response (ERSR) is a conserved program known to be deregulated in cancer and can mediate pro-survival signaling in the context of therapy. The ATF6, IRE1 and PERK pathways of the ERSR are known to be important mediators in the initiation of this signaling. In this research, we show for the first time that IR, a key component in glioblastoma therapy, can induce genes downstream of ATF6, IRE1 and PERK in glioblastoma cell lines. Furthermore, we identify the ATF6 and PERK-eIF2a-ATF4 pathways as important contributors to the radiation-response in glioblastoma. Our study began with the observation of protein and mRNA induction of targets associated with the ERSR in irradiated glioblastoma cell lines. In addition to ATF6 target genes, we observed robust induction of PERK target genes 48h after 6 Gy IR. This induction of PERK target genes was accompanied with increased phosphorylation of eIF2a in a time and dose-dependent manner. To evaluate the requirement of PERK for radiation-induced eIF2a phosphorylation, we used a specific inhibitor of PERK - GSK2606414, and found that PERK inhibition was sufficient to prevent radiation-induced eIF2a phosphorylation. We also analyzed expression of several genes downstream of PERK after treatment with GSK2606414, and found that PERK inhibition lead to 70-80% reduction in radiation-induction of downstream genes. Since ATF4 is downstream of PERK-eIF2a, we examined ATF4 expression in irradiated glioblastoma and found that it was also induced by radiation. Using RNA-interference, we found that knockdown of ATF4 reduced proliferation and clonogenic survival by 50%, and resulted in 38% increase in PARP cleavage in irradiated glioblastoma. We observed similar trends when we knocked down ATF6, suggesting that multiple aspects of the ERSR can contribute to the radiation response in glioblastoma. These results indicate that IR-induced activation of ER-stress signaling through PERK and ATF6 contributes to adaptive survival mechanisms in glioblastoma. Further characterization of the mechanism by which ATF6 and ATF4 mediate cell survival after irradiation may reveal novel targets for the enhancement of radiotherapy for glioblastoma. Citation Format: David Dadey, Vaishali Kapoor, Arpine Khudanyan, Dinesh Thotala, Dennis Hallahan. Radiation-induced ER stress contributes to survival in glioblastoma cell lines. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3323. doi:10.1158/1538-7445.AM2015-3323